OKYO Pharma Ltd. Form 6-K Summary
Reporting date: March 22, 2024. The filing reports clinical-trial results for OK-101 and includes a related news announcement as Exhibit 99.1. OKYO Pharma Ltd. is a foreign private issuer filing annual reports on Form 20-F.
Business Context and Trial
OK-101 is a 0.05% ophthalmic solution being evaluated for dry eye disease (DED). The reported first-in-human Phase 2 trial was a 240-patient, randomized, double-masked, placebo-controlled study assessing safety and efficacy.
Key Clinical Findings
- Statistically significant and durable reduction in ocular pain.
- Statistically significant improvement in tear film break-up time (TFBUT) throughout the study, described as a clinically important endpoint.
- Multiple symptomatic improvements based on both clinic-visit assessments and patient daily symptom diaries.
- The filing states that OK-101 achieved statistical significance for multiple signs and symptoms of DED, including ocular pain relief.
Financial Metrics and Liquidity
The filing does not provide revenue, profit or loss, cash-flow, margin, debt, liquidity, cash-balance, financing, or other financial metrics.
Changes Versus Prior Period
The filing text does not provide a prior-period financial or clinical comparison. It presents additional analyses from the 240-patient Phase 2 clinical data set.
Outlook, Risks, and Unusual Items
No financial guidance or commercialization outlook is provided. The results are clinical-trial findings and remain subject to further analysis, regulatory review, additional development, and the risks inherent in pharmaceutical development. The filing does not provide detailed safety data, adverse-event rates, effect sizes, p-values, confidence intervals, or regulatory timelines.
Exhibit 99.1 is furnished rather than filed and is not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference into other filings except where expressly stated.
Investor Verification Items
- Verify the full clinical data, including numerical effect sizes, statistical values, durability periods, and endpoint definitions.
- Review complete safety and adverse-event results for OK-101.
- Confirm the trial population, randomization, dosing schedule, analysis population, and handling of missing data.
- Assess whether the reported findings support the stated clinical relevance of TFBUT and ocular-pain improvements.
- Monitor subsequent regulatory, clinical-development, financing, and commercialization updates.